SecBot SecBot
Biotech Drug Report Generated Nov 12, 2026

ABCL385

ABCL·AbCellera Biologics Inc.
NEUTRAL
Drug Impact Rating1/10
Trial phase
No data found for ABCL385
Time to market
Not stated
Why 1/10
No hard, dated catalyst exists for ABCL385 because no public information about this drug candidate could be found. The drug does not appear in any clinical trial databases, SEC filings, press releases, or news coverage. ImpactScore defaults to 1 due to the lack of any identifiable program.
Actionable Insight NEUTRAL

No information could be found on a drug called ABCL385. AbCellera's lead proprietary programs are ABCL635 (menopause/hot flashes, Phase 2 complete, Phase 3 planned for 2027) and ABCL575 (atopic dermatitis, Phase 1). The next major catalyst for ABCL is the Phase 3 initiation for ABCL635 expected in 2027, plus the UBS Global Biopharma Conference presentation on November 17, 2026.

Price Chart

Loading chart...

Executive Summary

No public information could be found for a drug candidate called "ABCL385" from AbCellera Biologics (NASDAQ: ABCL). The name does not appear in any SEC filings, clinical trial registries, FDA databases, press releases, or news coverage. AbCellera's known proprietary pipeline consists of ABCL635 (Phase 2 completed for menopausal hot flashes, Phase 3 planned for 2027) and ABCL575 (Phase 1 for atopic dermatitis), along with partnered discovery programs. ABCL385 may be a very early preclinical program, a discontinued candidate, or a misidentification. The company trades at $11.95 with a market cap supported by its AI-driven antibody discovery platform and positive Phase 2 data for ABCL635.

How It Works

No information available. AbCellera is an antibody discovery and development company that uses an AI-powered platform to identify and engineer antibody drugs. Its known pipeline candidates include ABCL635 (targeting NK3R for menopausal hot flashes) and ABCL575 (targeting OX40L for atopic dermatitis).

Trial Status

No clinical trial data exists for ABCL385. AbCellera's lead proprietary program ABCL635 completed a Phase 2 trial for menopausal hot flashes with positive topline data announced August 10, 2026. ABCL575 is in Phase 1 for atopic dermatitis.

The Two-Sided Case

▲ Bull Case3
AbCellera has a strong balance sheet and analyst consensus is bullish: 16 Buy/Strong Buy ratings vs 2 Hold, with a mean price target of $18 (44.5% upside from $12.46).
Lead program ABCL635 showed positive Phase 2 data for menopausal hot flashes in August 2026, with Phase 3 planned for 2027, representing a large addressable market.
Insiders have been buying shares in 2026, including the CFO and directors, signaling confidence. Institutional accumulation from Bank of America and Marshall Wace in Q2 2026.
▼ Bear Case3
No public information exists for a drug called ABCL385, suggesting it may be a very early preclinical program, a discontinued candidate, or a typo. AbCellera has a history of pipeline setbacks, recently abandoning its OX40 antibody program.
AbCellera reported a Q3 2026 net loss of $40.8 million with only $10.6 million in revenue, indicating significant cash burn with no approved products generating meaningful revenue.
The stock has a 6-month return of +150%, meaning much optimism may already be priced in ahead of late-stage clinical data for ABCL635.

Upcoming Catalysts

  • UBS Global Biopharma Conference presentation on November 17, 2026
  • Phase 3 initiation for ABCL635 expected in 2027

Source Filing

The SecBot filing or press-release report that triggered this drug report:

AbCellera Biologics Inc. 8-K ABCL ·Originating report

Sources · 4

Hover a chip for the title
1 sec.gov2 fiercebiotech.com3 businesswire.com4 seekingalpha.com